Myriad Genetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MYGN and other ETFs, options, and stocks.

About MYGN

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. 

CEO
Samraat S Raha
CEOSamraat S Raha
Employees
2,700
Employees2,700
Headquarters
Salt Lake City, Utah
HeadquartersSalt Lake City, Utah
Founded
1991
Founded1991
Employees
2,700
Employees2,700

MYGN Key Statistics

Market cap
322.75M
Market cap322.75M
Price-Earnings ratio
-2.65
Price-Earnings ratio-2.65
Dividend yield
Dividend yield
Average volume
3.96M
Average volume3.96M
High today
$3.28
High today$3.28
Low today
$3.18
Low today$3.18
Open price
$3.21
Open price$3.21
Volume
588.61K
Volume588.61K
52 Week high
$8.59
52 Week high$8.59
52 Week low
$2.74
52 Week low$2.74

Stock Snapshot

The current Myriad Genetics(MYGN) stock price is $3.24, with a market capitalization of 322.75M. The stock trades at a price-to-earnings (P/E) ratio of -2.65.

On 2026-08-07, Myriad Genetics(MYGN) stock traded between a low of $3.18 and a high of $3.28. Shares are currently priced at $3.24, which is +1.7% above the low and -1.4% below the high.

The Myriad Genetics(MYGN)'s current trading volume is 588.61K, compared to an average daily volume of 3.96M.

During the past year, Myriad Genetics(MYGN) stock moved between $2.74 at its lowest and $8.59 at its peak.

During the past year, Myriad Genetics(MYGN) stock moved between $2.74 at its lowest and $8.59 at its peak.

MYGN News

Simply Wall St 4d
Why Myriad Genetics Is Down 49.0% After Cutting 2026 Revenue Outlook On Prenatal Weakness

In late July 2026, Myriad Genetics reported second-quarter results showing revenue of US$190.7 million versus US$213.1 million a year earlier, alongside a reduc...

Why Myriad Genetics Is Down 49.0% After Cutting 2026 Revenue Outlook On Prenatal Weakness
TipRanks 4d
Myriad Genetics price target lowered to $3 from $5.50 at Wells Fargo

Wells Fargo lowered the firm’s price target on Myriad Genetics (MYGN) to $3 from $5.50 and keeps an Equal Weight rating on the shares. The firm notes shares wer...

Simply Wall St 6d
Myriad Genetics Stock Sinks As Revenue Reset Deepens Loss Fears - simplywall.st

...

Myriad Genetics Stock Sinks As Revenue Reset Deepens Loss Fears - simplywall.st

Analyst ratings

56%

of 9 ratings
Buy
22.2%
Hold
55.6%
Sell
22.2%

People also own

Based on the portfolios of people who own MYGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.